Short description
A clinical-stage oncology biotech developing targeted anticancer drug delivery technologies for solid tumors
Description
Cend Therapeutics Inc. is a biopharmaceutical company dedicated to developing next generation cancer therapies that are designed to overcome the barriers of drug delivery to solid tumors. The novel drug delivery platform works highly specifically in cancer tissues, thereby having the potential to maximize efficacy while minimizing the toxicity and side effects usually associated with cancer treatments.
Numerous pre-clinical studies have demonstrated efficacy in multiple types of solid tumors, with a variety of therapeutic agents. The highly cancer-specific mechanism of action is well understood and characterized, increasing the confidence of translating the technology into a clinical breakthrough. The technology of the company is undergoing clinical testing in solid tumor patients.
Last funding
No Way
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
La Jolla, California, United States, North America
Founded on
December 1, 2015
Exited on
April 27, 2022
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$7890 - 12340
Sign in for full access
Founders
Erkki Ruoslahti, Kazuki Sugahara, Tambet (Tom) Teesalu